VL

Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology

Retrieved on: 
Tuesday, March 19, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Hospitals, Genetics, Clinical Trials, VL, Civil service commission, Givinostat, Neurology, Catholic higher education, Diarrhea, MAA, The Lancet, Magnetic resonance imaging, Safety, Abdominal pain, NDA, Manuscript, Rehabilitation, Lancet Neurology, University, OLE, EMA, Degenerative disease, Doctor of Philosophy, MD, European Medicines Agency, Duchenne muscular dystrophy, European Commission, NSAA, FDA, DMD, Pediatrics, PDUFA, Pharmaceutical industry

Italfarmaco S.p.A. announced today that the full results from the Company’s pivotal phase 3 EPIDYS clinical trial with givinostat in ambulant boys 6 years of age and older with Duchenne muscular dystrophy (DMD) have been published in The Lancet Neurology.

Key Points: 
  • Italfarmaco S.p.A. announced today that the full results from the Company’s pivotal phase 3 EPIDYS clinical trial with givinostat in ambulant boys 6 years of age and older with Duchenne muscular dystrophy (DMD) have been published in The Lancet Neurology.
  • The full manuscript, titled, “Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial,” is published on The Lancet Neurology website .
  • Participants attended study site visits every 12 weeks for 72 weeks and were evaluated for all endpoints within the study protocol.
  • Upon completion of the 18-month double-blind period, EPIDYS study participants were eligible to enroll in an open-label extension study (OLE study) to receive givinostat on an ongoing basis.

Global 6G Communications Research Report 2023: Terahertz and Optical Materials, Components 2024-2044 with Technology Roadmaps

Retrieved on: 
Monday, March 11, 2024
VL, Physics, 2D, Visibility, Nine Lives, Chapter Ten, Infrared, FSO, Communication, Executive, Component, Conclusion, SWOT, Graphene, Infogram, Terahertz, Samsung, Huawei, Atmosphere, NTT, Fused quartz

DUBLIN, March 11, 2024 /PRNewswire/ -- The "6G Communications: Terahertz and Optical Materials, Components 2024-2044 with 32 Forecast Lines, Technology Roadmaps" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 11, 2024 /PRNewswire/ -- The "6G Communications: Terahertz and Optical Materials, Components 2024-2044 with 32 Forecast Lines, Technology Roadmaps" report has been added to ResearchAndMarkets.com's offering.
  • This unique report identifies your huge optical material and component opportunities from 6G Communications as it becomes primarily an optical system.
  • Its 58 pages contain the necessary explanations, new infograms, opportunity identification, leading players, SOFT appraisals, roadmaps and 17 forecasts all 2023-2043.
  • Here are the vital photovoltaic and other optical material manufacturing technologies involved with more on both later in the report.

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, July 12, 2023
ACT, Part 1, Triple-negative breast cancer, TNBC, Index, Probability, HIV, VL, Pharmacy, Part, Diabetic neuropathy, DLT, Weakness, BOR, ART, Research, Observation, ASCO, Synthetic control method, EBITDA, Endometrial cancer, Patient, Treatment, Marathon Asset Management, Part Two, Viral load, MTD, SMR, Growth, Diagnosis, Toxic leukoencephalopathy, R, CD4, Ovarian cancer, American Conference, Hand, Conference, SD, Disease, PR, Safety, Prostate cancer, SORT1, Fine chemical, Pharmaceutical industry, Vaccine

For the second quarter of fiscal 2023, net sales of EGRIFTA SV® were $10,853,000 compared to $11,416,000 in the second quarter of fiscal 2022, representing a decrease of 4.9% year-over-year.

Key Points: 
  • For the second quarter of fiscal 2023, net sales of EGRIFTA SV® were $10,853,000 compared to $11,416,000 in the second quarter of fiscal 2022, representing a decrease of 4.9% year-over-year.
  • Trogarzo® net sales in the second quarter of fiscal 2023 amounted to $6,696,000 compared to $7,852,000 for the same quarter of 2022, representing a decrease of 14.7% year-over-year.
  • We ended the second quarter of fiscal 2023 with $25,369,000 in cash, bonds and money market funds.
  • In the second quarter of fiscal 2023, changes in operating assets and liabilities had a positive impact on cash flow of $4,643,000 (2022-positive impact of $10,701,000).

BIO-TECHNE SUCCESSFUL ON CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC

Retrieved on: 
Thursday, June 1, 2023
Probability, VL, VH, Marketing, Complementarity, Antibody, Bio-Techne, Animal, TIGIT, Higher Regional Court of Cologne, Sąd rejonowy, Court, R, Fine chemical, Miltenyi Biotec

MINNEAPOLIS, June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.

Key Points: 
  • MINNEAPOLIS, June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.
  • Specifically, the Court held "it has been proven that [Miltenyi's] TIGIT and CCR-7 antibodies are the result of reverse engineering of [Bio-Techne's] antibodies."
  • In addition to finding that Miltenyi has been marketing and selling these reverse engineered antibodies, the court determined that Bio-Techne is entitled to monetary damages and additional detailed information regarding the scope of Miltenyi's unlawful reverse engineering activities.
  • This discovery took place following suspicious purchasing activity from Miltenyi for these specific R&D Systems branded antibodies spanning more than a decade.

Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

Retrieved on: 
Thursday, May 4, 2023
AIDS Healthcare Foundation, Database, University, Senior, HIV, VL, Clinical trial, Chapel Hill, ART, University of North Carolina academic-athletic scandal, Observation, Synthetic control method, AIDS, Ibalizumab, EHR, Data, Patient, Viral load, TSX, SMR, CD4, American Conference, Conference, Treatment, Disease, Vaccine, Pharmaceutical industry

The ibalizumab study is thought to be the first matching-adjusted indirect treatment comparison (MAIC) study in HIV, an approach designed to facilitate a closely matched comparison from a synthesized, real-world population, when randomization to a control arm would be impractical or unethical.

Key Points: 
  • The ibalizumab study is thought to be the first matching-adjusted indirect treatment comparison (MAIC) study in HIV, an approach designed to facilitate a closely matched comparison from a synthesized, real-world population, when randomization to a control arm would be impractical or unethical.
  • Despite ibalizumab trial participants having more severe disease at baseline than non-ibalizumab controls, ibalizumab was associated with superior virologic outcomes.
  • Additionally, the same significance emerged for maintaining viral suppression, which was 18 times lower for real-world non-ibalizumab regimens compared to ibalizumab.
  • For both durability analyses, confidence intervals were wide but statistically significant (SMR-weighted HR: 18.36; 95% CI: 2.48, 135.68).

Trimble Announces Advanced Path Planning Technology, Taking the Next Step Toward Fully Autonomous Equipment for a Variety of Industries

Retrieved on: 
Wednesday, February 15, 2023
Cloud, BAUMA, Farm, Dynapac, Work, Software, AG, PT, VL, TRMB, Agriculture, Transport

WESTMINSTER, Colo., Feb. 15, 2023 /PRNewswire/ -- Trimble (NASDAQ: TRMB) announced today its new advanced path planning technology. This software-based technology gives Trimble end users and equipment manufacturers the ability to optimize and automate the trajectory, speed and overall path design of industrial equipment to increase efficiency of work. Manufacturers worldwide can now provide their customers with an easy-to-integrate, automated solution that works not only with Trimble systems, but also with an equipment manufacturer's existing system. The technology will also be available within Trimble Connected Farm and Trimble Construction Cloud, offering a seamless, end-to-end experience to Trimble end users.

Key Points: 
  • WESTMINSTER, Colo., Feb. 15, 2023 /PRNewswire/ -- Trimble (NASDAQ: TRMB) announced today its new advanced path planning technology.
  • The technology will also be available within Trimble Connected Farm and Trimble Construction Cloud, offering a seamless, end-to-end experience to Trimble end users.
  • By contrast, Trimble's advanced path planning technology offers automated, full path, complete project trajectory from entry to exit, including logistics points.
  • "Our new path planning technology is the next step in Trimble's vision of making fully autonomous solutions available across industries, regardless of brand, type of equipment or use case," said Finlay Wood, general manager, Off-Road Autonomy, Trimble.

Natural Language Processing Market Size to Reach USD 98.05 Billion in 2030 | Emergen Research

Retrieved on: 
Wednesday, December 21, 2022
Transfer, Human, Natural language processing, Organization, Uncertainty, USD, IQVIA, NLU, Language, Communication, Social media, Literature, GPS, Ambiguity, Mining, Natural language, University, Baidu, Lawyer, Growth, Hearing, Microsoft, University of Surrey, IBM, Prejudice, Law Society of British Columbia, Meta, NLP, Law society, Algorithm, Apple Inc., Cloud computing, SAS Institute Inc v World Programming Ltd, VL, Translation studies, Research, Artificial intelligence, Machine learning, Intelligence, Risk management

VANCOUVER, B.C., Dec. 22, 2022 /PRNewswire/ -- The natural language processing market size reached USD 12.43 Billion in 2021 and is expected to register a CAGR of 25.7% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Dec. 22, 2022 /PRNewswire/ -- The natural language processing market size reached USD 12.43 Billion in 2021 and is expected to register a CAGR of 25.7% during the forecast period, according to latest analysis by Emergen Research .
  • Surging demand for cloud-based NLP solutions to reduce overall costs and enhance scalability is a key factor driving natural language processing market revenue growth.
  • Natural Language Processing, or NLP, is the ability of computer software to interpret the natural language or human language as it is spoken and written.
  • The natural language processing market is expected to register a CAGR of 25.7% over the forecast period and revenue is projected to increase from USD 12.43 Billion in 2021 to USD 98.05 Billion in 2030.

Natural Language Processing Market Size to Reach USD 98.05 Billion in 2030 | Emergen Research

Retrieved on: 
Wednesday, December 21, 2022
Transfer, Human, Natural language processing, Organization, Uncertainty, USD, IQVIA, NLU, Language, Communication, Social media, Literature, GPS, Ambiguity, Mining, Natural language, University, Baidu, Lawyer, Growth, Hearing, Microsoft, University of Surrey, IBM, Prejudice, Law Society of British Columbia, Meta, NLP, Law society, Algorithm, Apple Inc., Cloud computing, SAS Institute Inc v World Programming Ltd, VL, Translation studies, Research, Artificial intelligence, Machine learning, Intelligence, Risk management

VANCOUVER, B.C., Dec. 22, 2022 /PRNewswire/ -- The natural language processing market size reached USD 12.43 Billion in 2021 and is expected to register a CAGR of 25.7% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Dec. 22, 2022 /PRNewswire/ -- The natural language processing market size reached USD 12.43 Billion in 2021 and is expected to register a CAGR of 25.7% during the forecast period, according to latest analysis by Emergen Research .
  • Surging demand for cloud-based NLP solutions to reduce overall costs and enhance scalability is a key factor driving natural language processing market revenue growth.
  • Natural Language Processing, or NLP, is the ability of computer software to interpret the natural language or human language as it is spoken and written.
  • The natural language processing market is expected to register a CAGR of 25.7% over the forecast period and revenue is projected to increase from USD 12.43 Billion in 2021 to USD 98.05 Billion in 2030.

Aftermath Islands Metaverse First to Deploy Blockchain Proof of Humanity by Liquid Avatar to Create Safer, Private Online Experience and Eliminate Usernames and Passwords

Retrieved on: 
Wednesday, October 19, 2022
Trust, Virgin Islands, Insurance, App Store (iOS/iPadOS), W3C, Non-fungible token, CBS, VL, Plague, E-commerce, Identity theft, KYC, Federal Trade Commission, Education, Knowledge, Privacy, Humanity, Google Play, Philosophy, Technology, Cyberbullying, Marketing, Behavior, CSE, Internet, Blockchain-based database, Social media, Ecosystem, Bullying, News, Database, Fraud, Solution, Cryptocurrency, Mobile phone, Online shopping, Metaverse, Lost Kingdoms II

The Meta Park Pass can then be presented to Aftermath Islands free Play-to-Earn game, Lost Kingdom of TSara, to play within the platform without establishing a traditional username and password.

Key Points: 
  • The Meta Park Pass can then be presented to Aftermath Islands free Play-to-Earn game, Lost Kingdom of TSara, to play within the platform without establishing a traditional username and password.
  • Aftermath Islands will also deploy the Meta Park Pass verifiable credential to access its Metaverse and other online programs as they become available.
  • Throughout the evolution of the Internet, both individuals and businesses have had great difficulty in establishing trust-based relationships and verification.
  • The system also includes features to create verifiable credentials and verify them, creating and supporting identity without the need of usernames and passwords.

Renovi Partners with Aftermath Islands to Launch its First-ever Metaverse and NFT Buildathon for Designers and Creators

Retrieved on: 
Wednesday, October 12, 2022
Decentraland, Virgin Islands, Non-fungible token, VL, FIAT, NFT, Program, Web3, Philosophy, Partnership, Student, Sport, CSE, Ecosystem, GPU, VR, Fraud, Documentation, Video game, Video game console, Online gambling, Cryptocurrency, Online shopping, Technology, Metaverse

Renovi , the first NFT marketplace created for architects and designers, has partnered with Aftermath Islands Metaverse to launch the Metaverses first-ever buildathon.

Key Points: 
  • Renovi , the first NFT marketplace created for architects and designers, has partnered with Aftermath Islands Metaverse to launch the Metaverses first-ever buildathon.
  • Co-founder at Renovi, Adonis Zachariades, said: This Buildathon is aimed at showcasing the Aftermath Islands metaverse and seeing what creators can build for it.
  • Winning designs will be shared by Aftermath Islands and Renovi before we drop the creations in our special buildathon collection on Aftermath Islands Marketplace.
  • David Lucatch, Managing Director of Aftermath Islands Metaverse, added: We are very excited to partner with Aftermath Islands and our participants to create the worlds first Metaverse Buildathon to support Aftermath Islands mandate of inclusiveness in the global online arena.